US Markets Closed

AI-assisted · Not financial adviceNot advice

AI-assisted · Not financial advice.

US Markets Closed

AI-assisted · Not financial adviceNot advice

US Markets Closed

AI-assisted · Not financial adviceNot advice

$LLY

Name: LLY (Eli Lilly) — Market Sentiment & Discussion
Creator: MarketMind
License: https://stockmarketsentimentai.com/methodology

Eli Lilly· 6/7/2026, 6:26:31 PM

Analyst & Event Activity

Analyst Rating Changes

May 26B of A SecuritiesBuy (reiterated)

Options positioning: Bullish — More betting on upside (1.2× more call than put volume today). Unusual bets on $1200 upside — 1.99× normal activity. analysts: 33 buy vs 3 sell.

Reddit: OptimisticAttention: Elevated

Community Take (7D)

Retail optimism for Eli Lilly is tempered by competition concerns with Novo Nordisk. News of promising developments for weight loss drugs suggests potential for growth.

The Story

News Summary

Eli Lilly's weight loss drug shows promise

Key Events

May 21:Eli Lilly's experimental drug retatrutide shows significant weight loss results.
May 20:Eli Lilly discloses a civil lawsuit alleging a rebate fraud scheme.
May 18:U.S. Supreme Court declines to hear Eli Lilly's appeal on whistleblower judgment.

Sentiment: 80% bullish / 20% neutral (early) → 60% bearish / 30% cautious / 10% bullish (late)

Impact: The narrative shifted from excitement over promising drug trials to concerns about legal issues impacting the company's reputation and stock performance.

Risks: legal challenges, market competition

Analyst ConsensusBuy (45 analysts)

Target: $1266 avg (+22% upside)

33 Buy · 9 Hold · 3 Sell

Signal

Divided

Confidence

60%

Based on curated news sources (not retail comments)

Over the last 7 days: Eli Lilly shows strong revenue growth and promising drug trials, but faces significant legal challenges that could impact its financials.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Mounjaro revenue jumped 125% to $8.66 billion last quarter.
✓Eli Lilly raised full-year revenue guidance to $82 to $85 billion.
✓Retatrutide demonstrated significant weight loss in trials, paving the way for regulatory approval.

Risk Factors

✗U.S. Supreme Court upheld a $194 million whistleblower judgment against Eli Lilly.
✗Concerns over a rebate fraud scheme costing the company more than $200 million.

Analyst target

22% upside · 10 analysts · $1119–$1400 range

▲ $1266

Earnings

EPS: $36.57 → $44.56 (2026 vs 2027)

▲ Expected to grow 22%

Insiders (90d)

0 buys, 2 sells

Last: SELL May 6· 32d ago

▼Net selling $15.8M

Analyze with AI yahoo!finance Reddit Answers

AI-assisted · Not financial advice.

$LLY - Eli Lilly | MarketMind | MarketMind

$LLY

Eli Lilly· 6/7/2026, 6:26:31 PM

Analyst & Event Activity

Analyst Rating Changes

May 26B of A SecuritiesBuy (reiterated)

Options positioning: Bullish — More betting on upside (1.2× more call than put volume today). Unusual bets on $1200 upside — 1.99× normal activity. analysts: 33 buy vs 3 sell.

Reddit: OptimisticAttention: Elevated

Community Take (7D)

Retail optimism for Eli Lilly is tempered by competition concerns with Novo Nordisk. News of promising developments for weight loss drugs suggests potential for growth.

The Story

News Summary

Eli Lilly's weight loss drug shows promise

Key Events

May 21:Eli Lilly's experimental drug retatrutide shows significant weight loss results.
May 20:Eli Lilly discloses a civil lawsuit alleging a rebate fraud scheme.
May 18:U.S. Supreme Court declines to hear Eli Lilly's appeal on whistleblower judgment.

Sentiment: 80% bullish / 20% neutral (early) → 60% bearish / 30% cautious / 10% bullish (late)

Impact: The narrative shifted from excitement over promising drug trials to concerns about legal issues impacting the company's reputation and stock performance.

Risks: legal challenges, market competition

Analyst ConsensusBuy (45 analysts)

Target: $1266 avg (+22% upside)

33 Buy · 9 Hold · 3 Sell

Signal

Divided

Confidence

60%

Based on curated news sources (not retail comments)

Over the last 7 days: Eli Lilly shows strong revenue growth and promising drug trials, but faces significant legal challenges that could impact its financials.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Mounjaro revenue jumped 125% to $8.66 billion last quarter.
✓Eli Lilly raised full-year revenue guidance to $82 to $85 billion.
✓Retatrutide demonstrated significant weight loss in trials, paving the way for regulatory approval.

Risk Factors

✗U.S. Supreme Court upheld a $194 million whistleblower judgment against Eli Lilly.
✗Concerns over a rebate fraud scheme costing the company more than $200 million.

Analyst target

22% upside · 10 analysts · $1119–$1400 range

▲ $1266

Earnings

EPS: $36.57 → $44.56 (2026 vs 2027)

▲ Expected to grow 22%

Insiders (90d)

0 buys, 2 sells

Last: SELL May 6· 32d ago

▼Net selling $15.8M

Analyze with AI yahoo!finance Reddit Answers